Acadia Pharma Shares Drop After Remlifanserin Trial Narrowly Misses Primary Endpoint

By Chris WackShares of Acadia Pharmaceuticals were lower after the company said the Phase 3 enabling topline results for its ongoing clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis missed its primary end…